<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="http://www.fda.gov/oc/datacouncil/stylesheets/spl/spl.xsl" type="text/xsl"?><document xmlns="urn:hl7-org:v3" xmlns:voc="http://www.hl7.org/v3/voc" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.fda.gov/oc/datacouncil/schemas/spl/spl.xsd">
<id root="FF1A2448-9461-42E4-EC22-49B412FE3532" />
<code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABELING" />
<title mediaType="text/x-hl7-title+xml">URISPAS<sup>&#174;</sup><br />brand of<br />flavoxate HCl<br />100 mg tablets</title>
<effectiveTime value="20060223" />
<setId root="c4eb0f29-5ccb-47e9-8fe4-696bf16c9bda" />
<versionNumber value="1" />
<author>
<time />
<assignedEntity>
<representedOrganization>
<name>ORTHO-McNEIL PHARMACEUTICAL, INC.</name>
</representedOrganization>
</assignedEntity>
</author>
<component>
<structuredBody>
<component>
<section>
<id root="81605243-0580-F0AD-FC35-5EBA841B116F" />
<effectiveTime value="20060223" />
<subject>
<manufacturedProduct>
<manufacturedMedicine>
<code code="17314-9220" codeSystem="2.16.840.1.113883.6.69" />
<name>URISPAS</name>
<formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED" />
<activeIngredient>
<quantity>
<numerator unit="mg" value="100">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="100" />
</numerator>
<denominator value="1">
<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="1" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="9C05J6089W" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>flavoxate hydrochloride</name>
<activeMoiety>
<activeMoiety>
<code code="3E74Y80MEY" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>flavoxate</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<asEntityWithGeneric>
<genericMedicine>
<name>flavoxate hydrochloride</name>
</genericMedicine>
</asEntityWithGeneric>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>calcium phosphate</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>hypromellose</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>magnesium stearate</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>polyethylene glycol</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>starch</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>talc</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<asContent>
<quantity>
<numerator value="100">
<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="100" />
</numerator>
<denominator value="1">
<translation value="1" />
</denominator>
</quantity>
<containerPackagedMedicine>
<code code="17314-9220-1" codeSystem="2.16.840.1.113883.6.69" />
<formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE" />
</containerPackagedMedicine>
</asContent>
</manufacturedMedicine>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255" />
<value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE"><originalText>white </originalText></value>
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE"><originalText>round</originalText></value>
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value unit="mm" value="10" xsi:type="PQ" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLCOATING" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="true" xsi:type="BL" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="1" xsi:type="INT" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255" />
<value xsi:type="ST">URISPAS</value>
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSYMBOL" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="false" xsi:type="BL" />
</characteristic>
</subjectOf>
<consumedIn>
<substanceAdministration>
<routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL" />
</substanceAdministration>
</consumedIn>
</manufacturedProduct>
</subject>
</section>
</component>
<component>
<section ID="s1">
<id root="4E3E491C-3358-05BF-F420-675E69E549F1" />
<code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION" />
<title mediaType="text/x-hl7-title+xml">DESCRIPTION</title>
<text><paragraph>URISPAS<sup>&#174;</sup> (flavoxate HCl) tablets contain flavoxate hydrochloride, a synthetic urinary tract spasmolytic.</paragraph><paragraph>Chemically, flavoxate hydrochloride is 2-piperidinoethyl 3-methyl-4-oxo-2-phenyl-4<content styleCode="underline">H</content>-1-benzopyran-8-carboxylate hydrochloride. The empirical formula of flavoxate hydrochloride is C<sub>24</sub>H<sub>25</sub>NO<sub>4</sub>&#8226; HCl. The molecular weight is 427.94. The structural formula appears below.</paragraph><renderMultiMedia ID="f1" referencedObject="mm1" /><paragraph>URISPAS<sup>&#174;</sup> is supplied in tablets for oral administration. Each round, white, film-coated  URISPAS<sup>&#174;</sup> tablet is debossed with the product name  URISPAS<sup>&#174;</sup> and contains flavoxate hydrochloride, 100 mg. Inactive ingredients consist of calcium phosphate, hypromellose, magnesium stearate, polyethylene glycol, starch and talc.</paragraph></text>
<effectiveTime value="20060223" />
<component>
<observationMedia ID="mm1">
<value mediaType="image/jpeg" xsi:type="ED"><reference value="urispas-01.jpg" /></value>
</observationMedia>
</component>
</section>
</component>
<component>
<section ID="s2">
<id root="B41AB376-92BA-17FE-C91B-D6BB47D9E54F" />
<code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION" />
<title mediaType="text/x-hl7-title+xml">CLINICAL PHARMACOLOGY</title>
<text><paragraph>Flavoxate hydrochloride counteracts smooth muscle spasm of the urinary tract and exerts its effect directly on the muscle.</paragraph><paragraph>In a single study of 11 normal male subjects, the time to onset of action was 55&#160;minutes. The peak effect was observed at 112 minutes. 57% of the flavoxate HCl was excreted in the urine within 24 hours.</paragraph></text>
<effectiveTime value="20060223" />
</section>
</component>
<component>
<section ID="s3">
<id root="19643E32-4C77-51C3-B119-AFD7FF56C66E" />
<code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION" />
<title mediaType="text/x-hl7-title+xml">INDICATIONS AND USAGE</title>
<text><paragraph>URISPAS<sup>&#174;</sup> (flavoxate HCl) is indicated for symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/urethrotrigonitis.  URISPAS<sup>&#174;</sup> is not indicated for definitive treatment, but is compatible with drugs used for the treatment of urinary tract infections.</paragraph></text>
<effectiveTime value="20060223" />
</section>
</component>
<component>
<section ID="s4">
<id root="F4665B2C-4044-FCB6-171E-78DE91782D41" />
<code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION" />
<title mediaType="text/x-hl7-title+xml">CONTRAINDICATIONS</title>
<text><paragraph>URISPAS<sup>&#174;</sup> (flavoxate HCl) is contraindicated in patients who have any of the following obstructive conditions: pyloric or duodenal obstruction, obstructive intestinal lesions or ileus, achalasia, gastrointestinal hemorrhage and obstructive uropathies of the lower urinary tract.</paragraph></text>
<effectiveTime value="20060223" />
</section>
</component>
<component>
<section ID="s5">
<id root="E8D79A4F-5F44-3C95-C9DB-8B238BF39BB4" />
<code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION" />
<title mediaType="text/x-hl7-title+xml">WARNINGS</title>
<text><paragraph>URISPAS<sup>&#174;</sup> (flavoxate HCl) should be given cautiously in patients with suspected glaucoma.</paragraph></text>
<effectiveTime value="20060223" />
</section>
</component>
<component>
<section ID="s6">
<id root="DC16F3C5-436C-E1A1-79C1-EF44C4EF8BF5" />
<code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION" />
<title mediaType="text/x-hl7-title+xml">PRECAUTIONS</title>
<effectiveTime value="20060223" />
<component>
<section ID="s7">
<id root="7DD2AEC2-99BD-2224-D4EE-9700CAE29D74" />
<code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION" />
<title mediaType="text/x-hl7-title+xml">Information for Patients:</title>
<text><paragraph>Patients should be informed that if drowsiness and blurred vision occur, they should not operate a motor vehicle or machinery or participate in activities where alertness is required.</paragraph></text>
<effectiveTime value="20060223" />
</section>
</component>
<component>
<section ID="s8">
<id root="6CAFB61E-C8C4-CA97-0642-74AA3618660D" />
<code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION" />
<title mediaType="text/x-hl7-title+xml">Carcinogenesis, Mutagenesis, Impairment of Fertility:</title>
<text><paragraph>Mutagenicity studies and long-term studies in animals to determine the carcinogenic potential of URISPAS<sup>&#174;</sup> (flavoxate HCl) have not been performed.</paragraph></text>
<effectiveTime value="20060223" />
</section>
</component>
<component>
<section ID="s9">
<id root="ACC191AE-8AA6-BEAC-877A-96282510CC02" />
<code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY" />
<title mediaType="text/x-hl7-title+xml">Pregnancy:</title>
<text><paragraph>Teratogenic Effects-Pregnancy Category B. Reproduction studies have been performed in rats and rabbits at doses up to 34 times the human dose and revealed no evidence of impaired fertility or harm to the fetus due to flavoxate HCl. There are, however, no well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</paragraph></text>
<effectiveTime value="20060223" />
</section>
</component>
<component>
<section ID="s10">
<id root="A2185263-F1B1-C65B-552F-9B2316C03F7F" />
<code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION" />
<title mediaType="text/x-hl7-title+xml">Nursing Mothers:</title>
<text><paragraph>It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when URISPAS<sup>&#174;</sup> is administered to a nursing woman.</paragraph></text>
<effectiveTime value="20060223" />
</section>
</component>
<component>
<section ID="s11">
<id root="4B05CA67-3497-B1E8-442D-4327CC866BA4" />
<code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION" />
<title mediaType="text/x-hl7-title+xml">Pediatric Use:</title>
<text><paragraph>Safety and effectiveness in children below the age of 12 years have not been established.</paragraph></text>
<effectiveTime value="20060223" />
</section>
</component>
</section>
</component>
<component>
<section ID="s12">
<id root="93032BFC-2E2B-23B7-6168-05942002988D" />
<code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION" />
<title mediaType="text/x-hl7-title+xml">ADVERSE REACTIONS</title>
<text><paragraph>The following adverse reactions have been observed, but there are not enough data to support an estimate of their frequency.</paragraph><paragraph><content styleCode="bold">Gastrointestinal:</content> Nausea, vomiting, dry mouth.</paragraph><paragraph><content styleCode="bold">CNS:</content>  Vertigo, headache, mental confusion, especially in the elderly, drowsiness, nervousness.</paragraph><paragraph><content styleCode="bold">Hematologic:</content> Leukopenia (one case which was reversible upon discontinuation of the drug).</paragraph><paragraph><content styleCode="bold">Cardiovascular:</content> Tachycardia and palpitation.</paragraph><paragraph><content styleCode="bold">Allergic:</content>  Urticaria and other dermatoses, eosinophilia and hyperpyrexia.</paragraph><paragraph><content styleCode="bold">Ophthalmic:</content> Increased ocular tension, blurred vision, disturbance in eye accommodation.</paragraph><paragraph><content styleCode="bold">Renal:</content>  Dysuria.</paragraph></text>
<effectiveTime value="20060223" />
</section>
</component>
<component>
<section ID="s13">
<id root="8537E73B-D7E8-6607-C2F4-A26FC0B492F4" />
<code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION" />
<title mediaType="text/x-hl7-title+xml">OVERDOSAGE</title>
<text><paragraph>The oral LD<sub>50</sub> for flavoxate HCl in rats is 4273 mg/kg. The oral LD<sub>50</sub> for flavoxate HCl in mice is 1837 mg/kg.</paragraph><paragraph>It is not known whether flavoxate HCl is dialyzable.</paragraph></text>
<effectiveTime value="20060223" />
</section>
</component>
<component>
<section ID="s14">
<id root="463FC625-9FD0-12A5-ED19-44855E188A22" />
<code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION" />
<title mediaType="text/x-hl7-title+xml">DOSAGE AND ADMINISTRATION</title>
<effectiveTime value="20060223" />
<component>
<section ID="s15">
<id root="DD45EA1F-AB22-AE74-625E-617C4B837B4A" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION" />
<title mediaType="text/x-hl7-title+xml">Adults and children over 12 years of age:</title>
<text><paragraph>One or two 100 mg tablets 3 or 4 times a day. With improvement of symptoms, the dose may be reduced. This drug cannot be recommended for infants and children under 12 years of age because safety and efficacy have not been demonstrated in this age group.</paragraph></text>
<effectiveTime value="20060223" />
</section>
</component>
</section>
</component>
<component>
<section ID="s16">
<id root="32FE6930-4C47-4356-A8DA-7843FD7F14B2" />
<code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION" />
<title mediaType="text/x-hl7-title+xml">HOW SUPPLIED</title>
<text><paragraph>URISPAS<sup>&#174;</sup> (flavoxate HCl), 100 mg, is supplied as round, white, film-coated tablets, debossed with the product name URISPAS<sup>&#174;</sup> in bottles of 100.</paragraph><paragraph>100 mg 100's: NDC 17314-9220-1</paragraph><paragraph>Store between 15&#176; and 30&#176;C (59&#176; and 86&#176;F).</paragraph><paragraph><content styleCode="bold">Rx only</content></paragraph><paragraph>Revision Date: AUGUST 2004</paragraph><paragraph>Manufactured by</paragraph><paragraph>Cardinal Health</paragraph><paragraph>Winchester, Kentucky 40391</paragraph><paragraph>Distributed by<br />ORTHO-McNEIL PHARMACEUTICAL, INC.<br />Raritan, New Jersey 08869</paragraph><paragraph> Printed in U.S.A.</paragraph><paragraph>631-10-843-2</paragraph></text>
<effectiveTime value="20060223" />
</section>
</component>
</structuredBody>
</component>
</document>
